A leading solution in target deconvolution and receptor identification
Retrogenix provides the leading solution for receptor and membrane target deconvolution. We specialise in discovering which human plasma membrane proteins are targeted by antibodies, proteins, small molecules and viruses.
Retrogenix identifies on behalf of its clients:
Target deconvolution is achieved by screening our clients’ molecules for interactions against the most comprehensive set of human plasma membrane proteins available in the context of the human cell. Now covering more than 3500 proteins, this represents the majority of known plasma membrane proteins.
Retrogenix has a rich client portfolio, including many global pharmaceutical / drug discovery companies and several notable academic institutions. We give our commercial clients a competitive advantage by identifying high quality, unexploited drug targets, and helping them to improve success rates at all stages of the drug research and development process.
29/05/2015 | Dr Freeth invited to present at Charles River Annual Biotech Symposium. Retrogenix's co-founder, Dr Jim Freeth, has accepted an invitation to present at this year's 'Biotechnology-Derived Therapeutics Symposium' in San Diego, CA. The event, which runs from 28th – 30th September 2015, will... | Read More
Retrogenix will be attending Next-Generation Antibodies and Protein Analysis: Tools and Technologies on the 15th and 16th June in Ghent, Belgium | Find out more
“…"no doubt" that the breakthrough in identifying EPCR was due to the Retrogenix screening tool” | Read more
Professor Thomas Lavstsen, University of Copenhagen